Genmab A (GMAB) Payables (2025 - 2026)
Genmab A (GMAB) posted Payables of $275.0 million for Q1 2026, up 0.73% on a QoQ basis from $273.0 million in Q4 2025.
Genmab A (GMAB) Payables (2025 - 2026) Analysis & Trends
Genmab A's Payables history runs 2 years deep, the most recent figure standing at $275.0 million for Q1 2026.
- Quarterly Payables changed N/A year-over-year to $275.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $275.0 million (changed N/A YoY) and the FY2025 annual result came in at $273.0 million, changed N/A from the prior year.
- Payables was $275.0 million for Q1 2026 at Genmab A, up from $273.0 million in the prior quarter.
- Across five years, Payables topped out at $275.0 million in Q1 2026 and bottomed at $273.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 5.74 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 10.62 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 8.69 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 423.55 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 489.30 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.03 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 80.54 Mn |
| 10 | Genmab A | 1.87 Bn | 350.00 Mn | 831.00 Mn | 275.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 275.00 Mn |
| Dec 31, 2025 | 273.00 Mn |